Free Trial

Revvity (NYSE:RVTY) Lowered to Hold Rating by Wall Street Zen

Revvity logo with Medical background

Revvity (NYSE:RVTY - Get Free Report) was downgraded by Wall Street Zen from a "buy" rating to a "hold" rating in a report released on Saturday.

RVTY has been the topic of several other research reports. Raymond James restated an "outperform" rating and set a $120.00 price objective (down previously from $145.00) on shares of Revvity in a report on Tuesday, April 29th. Robert W. Baird decreased their target price on Revvity from $127.00 to $125.00 and set an "outperform" rating on the stock in a research report on Tuesday, April 29th. UBS Group raised Revvity from a "neutral" rating to a "buy" rating and cut their target price for the stock from $145.00 to $115.00 in a research note on Thursday, May 1st. Barclays reduced their price objective on shares of Revvity from $140.00 to $110.00 and set an "overweight" rating on the stock in a report on Thursday, April 10th. Finally, The Goldman Sachs Group dropped their target price on Revvity from $140.00 to $125.00 and set a "buy" rating for the company in a research report on Tuesday, April 29th. Five research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Revvity currently has an average rating of "Moderate Buy" and a consensus target price of $125.64.

View Our Latest Report on Revvity

Revvity Trading Up 3.2%

Shares of Revvity stock traded up $2.89 during trading on Friday, reaching $92.22. The company's stock had a trading volume of 1,536,455 shares, compared to its average volume of 953,932. The firm's 50-day moving average is $96.30 and its two-hundred day moving average is $108.88. Revvity has a 52-week low of $88.01 and a 52-week high of $129.50. The company has a quick ratio of 3.03, a current ratio of 3.60 and a debt-to-equity ratio of 0.41. The company has a market cap of $10.87 billion, a price-to-earnings ratio of 41.73, a PEG ratio of 3.82 and a beta of 1.02.

Revvity (NYSE:RVTY - Get Free Report) last announced its quarterly earnings results on Monday, April 28th. The company reported $1.01 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.96 by $0.05. Revvity had a net margin of 9.81% and a return on equity of 7.68%. The firm had revenue of $664.76 million for the quarter, compared to the consensus estimate of $662.30 million. During the same quarter last year, the firm posted $0.98 EPS. The business's quarterly revenue was up 2.3% compared to the same quarter last year. On average, sell-side analysts anticipate that Revvity will post 4.94 earnings per share for the current year.

Hedge Funds Weigh In On Revvity

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. T. Rowe Price Investment Management Inc. lifted its position in shares of Revvity by 16.7% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 20,761,308 shares of the company's stock worth $2,317,170,000 after buying an additional 2,969,326 shares in the last quarter. Price T Rowe Associates Inc. MD grew its stake in Revvity by 25.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 9,563,911 shares of the company's stock valued at $1,011,863,000 after buying an additional 1,932,314 shares in the last quarter. EdgePoint Investment Group Inc. grew its position in shares of Revvity by 51.1% during the 4th quarter. EdgePoint Investment Group Inc. now owns 4,058,231 shares of the company's stock valued at $452,939,000 after purchasing an additional 1,372,456 shares in the last quarter. Norges Bank purchased a new position in shares of Revvity during the 4th quarter valued at $127,801,000. Finally, GAMMA Investing LLC grew its position in Revvity by 15,023.0% in the first quarter. GAMMA Investing LLC now owns 287,035 shares of the company's stock worth $30,368,000 after acquiring an additional 285,137 shares in the last quarter. Institutional investors own 86.65% of the company's stock.

About Revvity

(Get Free Report)

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.

Featured Articles

Analyst Recommendations for Revvity (NYSE:RVTY)

Should You Invest $1,000 in Revvity Right Now?

Before you consider Revvity, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Revvity wasn't on the list.

While Revvity currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Free Today: Your Guide to Smarter Options Trades Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings Preview: HUGE Stock Move Ahead
These 5 Small Stocks Could Deliver Huge Returns
ACT FAST! Congress Is POURING Into This Stock

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines